Teva and Biolojic launch IND studies for BD9 in atopic dermatitis and asthma
BD9 seeks to improve treatment outcomes for atopic dermatitis and asthma by targeting and inhibiting two main drivers of TH2-driven inflammation, addressing gaps in current therapies

Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry